Linked Life Data

9001760

Source:http://linkedlifedata.com/resource/pubmed/id/9001760

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1997-3-20
pubmed:abstractText
Because small cell lung cancer (SCLC) is a systemic malignancy, chemotherapy is the mainstay treatment for patients with all stages of this tumor. Many chemotherapeutic agents have activity against SCLC, and when combined in three- or four-drug regimens, they produce a response in 75% to 90% of patients. Median survival times for patients with limited disease range from 14 to 16 months, and a small proportion may be cured. For extensive stage patients, median survival is usually less than 1 year; 2 year disease-free survival is uncommon. Current research is focusing on ways to increase the dose intensity of chemotherapy delivery.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1052-3359
pubmed:author
pubmed:issnType
Print
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
113-33
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
The role of chemotherapy in the treatment of small cell lung cancer.
pubmed:affiliation
Department of Medicine, Toronto Hospital, University of Toronto, Ontario, Canada.
pubmed:publicationType
Journal Article, Review